EXHIBIT
NUMBER DESCRIPTION
- ----------- -------------------------------------------------------------------------------
10.24 Supply Agreement dated as of March 30, 1995 between Houba, Inc. and Zetapharm,
Inc. (incorporated by reference to Exhibit 10.14 to the March 8-K).
10.25 Form of 10% Convertible Subordinated Debenture (incorporated by reference to
Exhibit 6(a) to the June 10-Q).
10.26 Form of Redeemable Common Stock Purchase Warrant (incorporated by reference to
Exhibit 6(a) to the June 10-Q).
10.27 Form of 10% Convertible Subordinated Debenture (incorporated by reference to
Exhibit 4.1 to the Registrant's Current Report on Form 8-K dated December 4,
1995 (the "December 8-K")).
10.28 Form of Redeemable Common Stock Purchase Warrant (incorporated by reference to
Exhibit 4.2 to the December 8-K).
10.29 Form of 10% Convertible Debentures (incorporated by reference to Exhibit 99 to
the June 1996 10-Q).
10.30 Form of Redeemable Common Stock Purchase Warrant (incorporated by reference to
Exhibit 4.1 to Amendment No. 1 to the June 1996 10-Q).
22 Subsidiaries of the Registrant (incorporated by reference to Exhibit 22 to the
1993 Form 10-K).
24.1 Consent of Coleman & Rhine LLP(contained in the opinion to be filed as Exhibit
5 hereto).
*24.2 Consent of Grant Thornton LLP, independent certified public accountants.
*25 Power of Attorney.
- ------------
* Filed herewith
** To be filed by amendment
Exhibit 5
Coleman & Rhine LLP
1120 Avenue of the Americas
New York, New York 10036
September 11, 1996
Halsey Drug Co., Inc.
1827 Pacific Street
Brooklyn, New York 11233
Gentlemen:
We have acted as counsel to Halsey Drug Co., Inc., a New York corporation
(the "Company"), in connection with its Registration Statement on Form S-1 (the
"Registration Statement"), filed under the Securities Act of 1933, as amended
(the "Act"), relating to the proposed (i) offer and sale by certain shareholders
of the Company of up to 1,050,397 shares (the "Shares") of common stock, $.01
par value per share (the "Common Stock"), of the Company and (ii) issuance and
sale by the Company of up to 6,146,669 shares of Common Stock (the "Underlying
Shares") issuable to holders upon: (a) conversion of outstanding 10% Convertible
Subordinated Debentures due in July 2000 (the "July Debentures"); (b) conversion
of outstanding 10% Convertible Subordinated Debentures due in November 2000 (the
"November Debentures" ); (c) conversion of outstanding 10% Convertible
Subordinated Debentures due in August 2001 (the "August Debentures" and,
collectively with the July and November Debentures, the "Debentures"); (d)
payments of interest on the August Debentures; (e) exercise of outstanding
redeemable Common Stock Purchase Warrants expiring in November 2000 (the
"November Redeemable Warrants"); (f) exercise of outstanding redeemable Common
Stock Purchase Warrants expiring in August 2001 (the "August Redeemable
Warrants" and, collectively with the November Redeemable Warrants, the
"Redeemable Warrants"); (g) conversion of an outstanding Convertible Promissory
Note (the "Zatpack Note"); (h) exercise of outstanding Common Stock Purchase
Warrants (the "Bank Warrants"); and (i) exercise of outstanding Common Stock
Purchase Options (the "Options") (the Debentures, Redeemable Warrants, Zatpack
Note, Bank Warrants and Options are sometimes referred to collectively as the
"Convertible Securities").
In such capacity we have examined originals or copies, certified or
otherwise identified to our satisfaction, of the Company's Certificate of
Incorporation and By-Laws as presently in effect, minutes and other instruments
evidencing actions taken by the Company's directors, the Registration Statement
and
exhibits thereto and such other documents and instruments relating to the
Company and the issuance of the Underlying Shares and the Shares as we have
deemed necessary or appropriate under the circumstances.
We are members of the Bar of the State of New York and do not represent
ourselves to be expert in the laws of any other state or jurisdiction, except
with respect to the federal laws of the United States of America.
Based on the foregoing, it is our opinion that:
1. The Company has been duly organized and is validly existing under the
laws of New York and has authorized capital stock consisting of 20,000,000
shares of Common Stock.
2. The Shares have been duly and validly issued, and are fully paid and
non-assessable shares of Common Stock of the Company, with no personal liability
attached to the ownership thereof.
3. The Underlying Shares issuable upon the exercise or conversion, as the
case may be, of the Convertible Securities have been duly authorized and
reserved for issuance upon exercise or conversion of the Convertible Securities,
and such Underlying Shares, when issued and paid for upon exercise or conversion
of the Convertible Securities in accordance with the respective terms thereof,
will be legally issued, fully paid and non-assessable shares of Common Stock of
the Company.
We hereby consent to (i) the use of this opinion as an exhibit to the
Registration Statement and as an exhibit to any application under the securities
or other laws of any state of the United States, which relates to the offering
that is the subject of this opinion, and (ii) the reference to this firm under
the heading "Legal Matters" in the prospectus which is contained in the
Registration Statement. By giving the foregoing consent, we do not admit that we
come within the category of persons whose consent is required under Section 7 of
the Act.
This opinion is as of the date hereof and is limited to the laws in effect
as of the date hereof. We undertake no obligation to advise you of any change,
whether legal or factual, in any matters set forth herein.
This opinion is furnished to you in connection with the filing of the
Registration Statement, and is not to be used, circulated, quoted or otherwise
relied upon for any other purpose, except as expressly provided in the preceding
paragraphs.
Very truly yours,
COLEMAN & RHINE LLP
EXHIBIT 10.5 (IV)
AMENDMENT SIX TO CREDIT AGREEMENT
This Amendment Six is dated as of August 6, 1996 and is made by and among
Halsey Drug Co., Inc., a New York corporation (the "Borrower"), The Chase
Manhattan Bank, as successor in interest to The Chase Manhattan Bank (National
Association) ("Chase"), Israel Discount Bank of New York ("IDB"), The Bank of
New York ("BNY," and together with Chase and IDB, the "Banks") and The Chase
Manhattan Bank, as successor in interest to The Chase Manhattan Bank (National
Association), in its capacity as agent for the Banks (in such capacity, the
"Agent").
WHEREAS, the Borrower, the Banks and the Agent are parties to a Credit
Agreement dated as of December 22, 1992;
WHEREAS, such Credit Agreement was amended by Amendment One ("Amendment
One") dated as of June 4, 1993, executed by each of the Borrower, the Banks and
the Agent, further amended by Amendment Two ("Amendment Two") dated as of
January 12, 1994, further amended by Amendment Three ("Amendment Three") dated
as of May 12, 1994, further amended by Amendment Four ("Amendment Four") dated
as of July 21, 1994, further amended by Amendment Five ("Amendment Five") dated
as of March 21, 1995 and further amended by a letter agreement (the "November
16, 1995 Letter Agreement") dated November 16, 1995 (such Credit Agreement, as
so amended, the "Credit Agreement"); and
WHEREAS, the Borrower has requested the Banks and the Agent to further amend
the Credit Agreement as provided herein in order to, inter alia, facilitate its
ability to comply with the terms and conditions thereof and the Banks have
consented to do so on the terms and subject to the conditions set forth herein
and in the other Restructuring Documents;
NOW, THEREFORE, in consideration of the premises and under the authority of
Section 5-1103 of the New York General Obligations Law, the Borrower, the Banks
and the Agent agree as follows:
1. Defined Terms. Unless otherwise defined herein, capitalized terms used
herein shall have the meanings ascribed to them in the Credit Agreement.
2. Amendment. Effective as of the later of (i) the date hereof and (ii) the
satisfaction of all conditions specified in Section 3 hereof, the Credit
Agreement is hereby amended as follows:
2.1 The terms "this Agreement," "hereunder" and similar references in
the Credit Agreement shall be deemed to refer to the Credit Agreement as
amended by Amendment One, Amendment Two, Amendment Three, Amendment Four,
Amendment Five, the November 16, 1995 Letter Agreement and further amended
hereby.
2.2 Section 1.1 of the Credit Agreement is amended by changing the
definitions of "Expiration Date," and "Restructuring Documents" to read, in
their entirety, as follows:
"Expiration Date" means the earlier of (i) December 31, 1996 and (ii)
the date upon which the Commitments are terminated or reduced in amount
to zero; provided that if all liabilities are declared due and payable
upon an Event of Default pursuant to the provisions of Part 11, the
Expiration Date shall be the date such liabilities are declared due and
payable.
"Restructuring Documents" means Amendment Two, Amendment Three,
Amendment Four, Amendment Five, the November 16, 1995 Letter Agreement,
Amendment Six, the Warrants, the Warrant Amendments, the Registration
Rights Agreements, the New Warrants, the Second Warrant Amendments and
any documents delivered or entered into pursuant to or in connection with
Amendment Two, Amendment Three, Amendment Four, Amendment Five, the
November 16, 1995 Letter Agreement, Amendment Six, the Warrants,
1
the Warrant Amendments, the Registration Rights Agreements, the New
Warrants or the Second Warrant Amendments, in each case as such
agreements or documents may be amended or replaced from time to time.
2.3 Section 1.1 of the Credit Agreement is further amended by adding the
following definitions at the appropriate places in the alphabetical order:
"Amendment Six" means Amendment Six to Credit Agreement among the
Borrower, Chase, IDB, BNY and the Agent dated as of August , 1996
amending the terms of this Agreement.
"Amendment Six Effective Date" means the later of (i) the date as of
which Amendment Six was executed and (ii) date of the satisfaction of all
conditions to effectiveness specified in Section 3 of Amendment Six.
"November 16, 1995 Letter Agreement" means the letter agreement dated
November 16, 1995 among the Borrower, the Banks and the Agent.
2.4 Section 2.3 of the Credit Agreement is amended by adding the
following sentences at the end thereof:
2.3 On the Expiration Date the Borrower shall also pay to the Agent,
for the account of the Banks, a commitment fee at the rate of 1% per
annum, such commitment fee to accrue daily from and including September
1, 1995 to but excluding the date upon which all of the Loans are repaid
in full, on the amount of the total Commitments (the total Commitments
being the outstanding principal balance of the Loans) for each day during
such period.
2.5 Section 2.4 of the Credit Agreement is amended by adding the
following sentence at the end thereof
2.4 Agency Fees. On the Expiration Date the Borrower shall also pay
to the Agent for its account an agency fee of $2,500 per month (or
portion thereof) for the period from September 1, 1995 through July 31,
1996 and $4,000 per month (or portion thereof) from August 1, 1996
through date upon which all of the Loans are repaid in full.
2.6 Section 2.5.2 of the Credit Agreement is amended to read, in its
entirety, as follows:
2.5.2 On the Expiration Date, the Borrower shall pay to the Agent for
the account of each Bank a fee equal to 3% of the total Commitments (the
total Commitments being the principal balance of the Loans) of all of the
Banks as of August 31, 1995, minus any portion of such fee that was
previously paid in connection with the November 16, 1995 Letter
Agreement, to be paid to the Banks pro rata in accordance with their Pro
Rata Commitment on August 31, 1995.
2.7 The financial covenants in Part 9 of the Credit Agreement are hereby
amended and will be reflected in a subsequent amendment to the Credit
Agreement as the parties hereto shall agree in good faith.
2.8 Part 10 of the Credit Agreement is amended by adding the following
after Section 10.11:
10.12 The Borrower shall not, and shall not permit any of its
Subsidiaries or any joint venture to which it or any of its Subsidiaries
is a party (regardless of whether or not such joint venture is itself a
Subsidiary of the Borrower) to, amend, modify or waive, or consent to any
amendment, modification, or waiver of, either orally or in writing, any
provision of any security, instrument, agreement or other document
governing any obligation of the Borrower, any Subsidiary of the Borrower
or any joint venture to which the Borrower or any Subsidiary of the
Borrower is a party (regardless of whether or not such joint venture is
itself a Subsidiary of the Borrower), in respect of any Indebtedness,
including, without limitation, any provision
2
of the convertible subordinated debentures issued by the Borrower
regarding the conversion of such debentures or the terms of subordination
of payment of such debentures, nor shall the Borrower enter into or
incur, or permit any of its Subsidiaries or any joint venture to which it
or any of its Subsidiaries is a party (regardless of whether or not such
joint venture is itself a Subsidiary of the Borrower) to enter into or
incur, obligations with respect to Indebtedness for borrowed money or in
respect of bonds, notes, debentures or other such instruments, other than
those obligations in existence on the Amendment Six Effective Date or
arising under documents delivered to the Agent and the Banks in
connection with Section 3.5 of Amendment Six; in each case without the
prior written consent of the Controlling Banks.
10.13 The Borrower shall not, and shall not permit any of its
Subsidiaries or any joint venture to which it or any of its Subsidiaries
is a party (regardless of whether or not such joint venture is itself a
Subsidiary of the Borrower) to, make any payments with respect to any
obligation of the Borrower, any Subsidiary of the Borrower or any joint
venture to which the Borrower or any Subsidiary of the Borrower is a
party (regardless of whether or not such joint venture is itself a
Subsidiary of the Borrower) with respect to any Indebtedness, the payment
of which is in any manner subordinated to the payment of the Obligations,
including, without limitation, the convertible subordinated debentures
issued by the Borrower, without the prior written consent of the
Controlling Banks, other than (x) mandatory payments of interest made in
accordance with the subordination provisions applicable to such
obligations and (y) in the case of the Borrower's convertible
subordinated debentures and any other obligations that may, by their
terms, be converted into equity other than at the option of the holder
thereof, the minimum mandatory interest payments required to be paid
prior to the earliest date upon which such obligation may be converted
into equity other than at the option of the holder thereof.
2.9 Section 11.5 of the Credit Agreement is amended to read, in its
entirety, as follows:
11.5 Borrower shall default in the performance of (a) any of the
covenants contained in Section 8.13, 10.12 or 10.13 or (b) any other
covenant, condition, or provision hereof or of any other Loan Document
and, solely in the case of (b), such default shall not be remedied within
a period of fifteen (15) days after written notice thereof to the
Borrower from any Bank.
2.10 Part 13 of the Credit Agreement is amended by amending Section
13.4.1 to read, in its entirety, as follows:
13.4.1 The Borrower agrees to pay or reimburse each Bank for
paying: (a) all reasonable costs and expenses of each Bank (excluding
fees and disbursements of each Bank's legal counsel except as
provided in clauses (b), (c) and (f) below) in connection with the
preparation, execution and delivery of, the making of Loans under,
and the enforcement and/or collection of, this Agreement, the Notes,
the Loan Documents, Amendment One, Amendment Two, Amendment Three,
Amendment Four, Amendment Five, the November 16, 1995 Letter
Agreement, Amendment Six, the Warrants, the Warrant Amendments, the
New Warrants, the Second Warrant Amendments, the Registration Rights
Agreements or any other document referred to herein; (b) the
reasonable fees, charges, costs and expenses, if any, of Nixon,
Hargrave, Devans & Doyle, special counsel to the Banks, in connection
with the preparation, execution and delivery of this Agreement, the
Notes, the Loan Documents, Amendment One and other related or
ancillary documents; (c) the reasonable fees, charges, costs and
expenses of Howard, Darby & Levin, special counsel to the Banks, and
of counsel to each of the Banks (whether outside counsel or counsel
who are employees of the Agent or any of the Banks, provided,
however, the Borrower shall not be obligated to pay fees of counsel
who are
3
employees of the Agent or any of the Banks in connection with and
involved in negotiating, drafting, reviewing or preparing of
Amendment Five or Amendment Six) in connection with the negotiation,
preparation, execution and delivery of the Loan Documents, Amendment
Two, Amendment Three, Amendment Four, Amendment Five, the November
16, 1995 Letter Agreement, Amendment Six and the other Restructuring
Documents; (d) all transfer, stamp, documentary or other similar
taxes, assessments or charges levied by any governmental or revenue
authority in respect of this Agreement, the Notes, the Loan Documents
or any other documents related to any of the foregoing; (e) all
costs, expenses, taxes, assessments and other charges incurred in
connection with any filing, registration, recording or perfection of
any Lien contemplated by this Agreement, the Notes, the Loan
Documents or any other documents related to any of the foregoing; and
(f) any and all reasonable and necessary expenses paid or incurred by
each Bank (including, without limitation, reasonable attorneys' fees,
charges, costs and expenses of Howard, Darby & Levin, special counsel
to the Banks, and of counsel to each of the Banks, whether outside
counsel or counsel who are employees of the Agent or any of the
Banks), if any, in connection with the enforcement or collection of
this Agreement, the Notes, the Loan Documents, the Restructuring
Documents or any guaranty or collateral security for Indebtedness
under the Notes arising after the occurrence of any event, condition
or act which with notice or lapse of time or both would constitute an
Event of Default, unless such occurrence is cured by Borrower within
any applicable grace period or such reimbursement is not required by
the terms of such consent or waiver granted by Bank in respect of
such occurrence. The obligations of Borrower under this Section
13.4.1 shall survive the payment of the Notes.
3. Conditions to Effectiveness. This Amendment Six shall not become
effective except upon the fulfillment of each of the conditions set forth in
Sections 3.1 through 3.9 inclusive and the Agent and the Banks shall have
additionally received all the documents and payments described below, each
document being in form and substance reasonably satisfactory to the Bank and
their counsel.
3.1 Receipt of Counterparts. The Agent and the Banks shall have received
signed counterparts of this Amendment Six from the Borrower and each of the
Banks.
3.2 Interest and Principal Payments. The Agent shall have received (in
immediately available funds) for the ratable benefit of the Banks: (a) all
interest payments due or scheduled to fall due on or before the first
Business Day of August, 1996 (provided, however, that if the interest
payment scheduled to fall due on the first Business Day of August, 1996 is
made prior to such date, it shall be held in the escrow described in clause
(b) below and paid by the Agent to the Banks on the first Business Day of
August, 1996), (b) an amount equal to the interest payments that will be due
and payable on the first Business Day of September, 1996 and the first
Business Day of October, 1996 (assuming no further reduction of the
Commitments after the effective date of Amendment Six), such amount
(together with any amount required to be placed in escrow in respect of the
August 1, 1996 interest payment) to be placed in escrow with the Agent for
the benefit of the Banks and to be paid (without any further authorization
from the Borrower) by the Agent to the Banks to satisfy any obligation of
the Borrower to pay interest under the Credit Agreement and (c) a payment of
not less than $200,000, to be applied to reduce the outstanding principal
balance of the Loans.
3.3 Fees and Expenses. The Agent and the Banks shall have received
evidence that the Borrower has paid all amounts required to be paid in
accordance with Section 13.4.1, including, without limitation, all legal
fees and expenses of counsel to Banks in respect of which invoices have been
issued on or before the effective date of Amendment Six.
3.4 Sources and Uses Statements. The Agent and the Banks shall have
received statements showing the sources and uses of the proceeds of (a) the
offering made pursuant to the Private
4
Placement Memorandum dated June 29, 1995, (b) the offering made pursuant to
the Private Placement Memorandum dated November 20, 1995 and (c) any other
offering presently contemplated by the Borrower.
3.5 Other Debt Instruments. The Agent and the Banks shall have received
certified copies of the securities, instruments, agreements and other
documents governing all debt obligations (other than the Obligations owed to
the Banks under the Credit Agreement) of the Borrower, each Subsidiary of
the Borrower and each joint venture to which the Borrower or any Subsidiary
of the Borrower is a party (regardless of whether or not such joint venture
is itself a Subsidiary of the Borrower), including, without limitation,
obligations that are or may be convertible into equity of the Borrower and
any new debt obligations the Borrower or any Subsidiary intends to incur,
together with a certificate of the Chief Executive Officer of the Borrower
stating that (a) such copies are true and correct copies, (b) such copies
represent all of the instruments, documents and agreements relating to debt
obligations to which the Borrower, any Subsidiary of the Borrower or any
joint venture to which the Borrower or any Subsidiary of the Borrower is a
party (regardless of whether or not such joint venture is itself a
Subsidiary of the Borrower)is a party or by which any of its assets is
bound, (c) neither the Borrower nor any Subsidiary nor or any joint venture
to which the Borrower or any Subsidiary of the Borrower is a party
(regardless of whether or not such joint venture is itself a Subsidiary of
the Borrower) has issued, or is a party to, any securities, instruments,
agreements or other documents evidencing or relating to obligations to pay
money other than those included in such copies and (d) such instruments,
agreements and documents are in full force and effect and have not been
modified, amended or waived in any manner, except as disclosed explicitly in
writings, copies of which are included therewith; and all such securities,
instruments, agreements and other documents, shall be in form and substance
acceptable to the Agent and the Banks in their sole and absolute discretion
(including, without limitation, with respect to provisions governing
convertibililty and subordination).
3.6 Resolutions. The Agent and the Banks shall have received certified
copies of the resolutions of the Board of Directors of the Borrower, Houba,
Inc., Blue Cross Products, Inc., Halsey Pharmaceuticals, Inc. and The
Medi-Gum Corporation authorizing and consenting to Amendment Six of the
Credit Agreement and the effects upon any Security Documents to which each
of the above-mentioned corporations is a party.
3.7 Shareholder Consent. The Agent and the Banks shall have received
certified copies of consents of the Shareholders of Houba, Inc., Blue Cross
Products, Inc., Halsey Pharmaceuticals, Inc. and The Medi-Gum Corporation
approving and ratifying the consent of each such corporation to Amendment
Six of the Credit Agreement and the effect upon any Security Documents to
which each of the above-mentioned corporations is a party.
3.8 Opinion of Counsel. The Agent and the Banks shall have received an
opinion of counsel to the Borrower in respect of this Amendment Six in
substantially the form of Exhibit A annexed hereto.
3.9 Other Documents. The Borrower and each Subsidiary that is a party to
any Loan Document shall have executed and delivered to the Agent any
instruments or documents needed or, in the determination of the Agent and
the Banks, advisable, to effectuate the provisions of the Loan Documents
(including prior amendments thereto) including, without limitation, all
Uniform Commercial Code financing statements needed or advisable to evidence
the perfection of the Liens granted under the Security Documents.
5
4. Representations and Warranties. The Borrower represents and warrants,
with respect to itself and its subsidiaries, to the Agent and each Bank, as of
the date hereof, that:
4.1 The Borrower is indebted to the Banks, and the outstanding principal
amount of the Loans is $3,394,574.79 as of the date of execution of this
Amendment Six, and interest is continuing to accrue on unpaid principal,
together with other fees, costs, and expenses incurred and to be incurred by
the Banks;
4.2 The Loan Documents are in full force and effect, were duly executed
by the parties hereto, constitute legal, valid and binding agreements and
obligations of the parties thereto, are enforceable in accordance with their
respective terms against the parties thereto and are hereby reaffirmed and
ratified, as modified by this Amendment Six;
4.3 This Amendment Six has been duly executed by the Borrower and
constitutes a legal, valid and binding agreement and obligation of the
Borrower, enforceable against the Borrower in accordance with its terms.
4.4 The Borrower has, to the best of its knowledge, no defense,
counterclaim, offset, cross-claim, claim or demand of any kind or nature
whatsoever which can be asserted to reduce or eliminate all or any part of
its liability to repay the Loans, which (immediately prior to the
effectiveness hereof) are in default and remains due, owing and unpaid and
in any event all defenses, counterclaims, offsets, cross-claims, claims and
demands are released under Section 5.1;
4.5 The security interests and Liens granted to the Agent for the
benefit of the Banks in the Collateral are valid, in existence, attached,
duly perfected and not subject to any pending dispute or direct or indirect
challenge or attack or, to the knowledge of the Borrower, any threatened
dispute or direct or indirect challenge or attack by any party other than
the Borrower, and the grant of such security interests and Liens to the
Agent for the benefit of the Banks is hereby reaffirmed; and
4.6 Nothing but full and complete performance of all the Obligations
under the Loan Documents and payment of the Loans in full shall satisfy and
discharge the Borrower's liability to the Banks under the Loan Documents.
5. Release and Indemnification.
5.1 The Borrower on behalf of itself and its successors and assigns,
hereby forever and irrevocably releases the Agent and each Bank, and their
respective officers, directors, representatives, agents, attorneys,
employees, affiliates, subsidiaries, successors and assigns, from any and
all claims, demands, suits, cross-claims, causes of action, assertions,
liabilities, debts, defenses, counterclaims or offsets of any kind or nature
whatsoever existing on the date hereof, whether known or unknown, pertaining
to, connected with or arising out of the Credit Agreement, Amendment One,
Amendment Two, Amendment Three, Amendment Four, Amendment Five, the November
16, 1995 Letter Agreement, this Amendment Six, the transactions described in
the Credit Agreement, Amendment One, Amendment Two, Amendment Three,
Amendment Four, Amendment Five, the November 16, 1995 Letter Agreement
and/or this Amendment Six, the Loan Documents, or any document, instrument
or agreement entered into in connection therewith or herewith or referred to
therein or herein or any other obligation of the Borrower to the Agent or
any Bank or any of their respective affiliates (collectively, "Claims"). The
parties acknowledge that Section 5.1 does not and shall not apply to Claims
that arise after the date hereof.
5.2 The Borrower further agrees to defend, protect, indemnify, and hold
harmless the Agent, the Banks, each of their Affiliates and each of the
respective officers, directors, employees, agents, attorneys and consultants
(collectively called the "Indemnitees") of the Agent, the Banks and their
Affiliates from and against any and all liabilities, obligations, losses,
damages, penalties, actions, judgments, suits, claims, costs, expenses and
disbursements of any kind or nature whatsoever
6
(including, without limitation, the reasonable fees and disbursements of
counsel for such Indemnitees in connection with any investigative,
administrative or judicial proceeding, whether or not such Indemnitees shall
be designated a party thereto), imposed on, incurred by, or asserted against
such Indemnitees, whether direct, indirect, or consequential and whether
based on any federal or state laws or other statutory regulations,
including, without limitation, securities and commercial laws and
regulations, under common law or at equity, or on contract or otherwise,
including any liability and costs under federal, state or local
environmental, health or safety laws, regulations, or common law principles,
arising from or in connection with any Claims.
5.3 The Borrower acknowledges that it has been advised by counsel with
respect to this Agreement and the release and indemnity contained herein.
6. Effect on Loan Documents.
6.1 Except as expressly amended above, the terms and conditions of the
Credit Agreement and the other Loan Documents shall remain in full force and
in effect and are hereby ratified and confirmed. Although counsel for the
Agent has prepared the Credit Agreement and this Amendment Six, the Borrower
waives any right to require that any ambiguity or question about the terms
thereof or hereof be construed against the Agent or the Banks.
6.2 Except as expressly provided in this Amendment Six, nothing
contained herein shall constitute a waiver, release or modification of any
of the Agent's or the Banks' rights and remedies under, or any of the terms
and conditions of, the Loan Documents. The Agent and the Banks expressly
reserve all of their rights and remedies under the Loan Documents. Upon the
satisfaction of the conditions to effectiveness set forth in Section 3 this
Amendment Six, including, without limitation, the making of all payments
referred to therein, the Agent and the Banks waive any and all Defaults and
Events of Default under the Credit Agreement on or prior to the Amendment
Six Effective Date, provided, however, nothing contained herein shall be
deemed to constitute a waiver of any Default or Event of Default under the
Credit Agreement (as amended by this Amendment Six), which Default or Event
of Default is in existence after the Amendment Six Effective Date.
7. GOVERNING LAW. THIS AMENDMENT SIX SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO ANY
CONFLICTS-OF-LAW RULES WHICH WOULD REQUIRE THE APPLICATION OF THE LAWS OF ANY
OTHER JURISDICTION.
8. WAIVER OF JURY TRIAL. THE PARTIES HERETO HEREBY WAIVE ANY RIGHT TO A JURY
TRIAL FOR ANY CONTROVERSY ARISING OUT OF OR PERTAINING TO THIS AMENDMENT SIX,
THE LOAN DOCUMENTS, THE RESTRUCTURING DOCUMENTS OR ANY TRANSACTION DESCRIBED
HEREIN OR THEREIN.
9. Headings. Section headings in this Amendment Six are included herein for
convenience of reference only and shall not constitute a part of this Amendment
Six for any other purpose.
10. Execution in Counterparts. This Amendment Six may be executed in any
number of counterparts and by different parties hereto in separate counterparts,
each of which when so executed and delivered shall be deemed to be an original
and all of which taken together shall constitute but one and the same
instrument. Execution and delivery of this Amendment Six by facsimile shall be
as effective as physical delivery of a manually executed counterpart.
7
HALSEY DRUG CO., INC.
By: ______________________________
Name:
Title:
THE CHASE MANHATTAN BANK,
as successor in interest to
THE CHASE MANHATTAN BANK, N.A.
By: ______________________________
Name:
Title:
THE BANK OF NEW YORK
By: ______________________________
Name:
Title:
ISRAEL DISCOUNT BANK OF NEW YORK
By: ______________________________
Name:
Title:
THE CHASE MANHATTAN BANK
as successor in interest to
THE CHASE MANHATTAN BANK, N.A.,
as Agent
By: ______________________________
Name:
Title:
8
EXHIBIT 24.2
CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
We have issued our report dated March 29, 1996, which included an
explanatory paragraph with respect to the Company's ability to continue as a
going concern, accompanying the financial statements of Halsey Drug Co., Inc.
contained in the Registration Statement and Prospectus. We consent to the use of
the aforementioned report in Amendment No. 1 to the Registration Statement and
Prospectus, and to the use of our name as it appears under the caption
"Experts".
GRANT THORNTON LLP
New York, New York
September 10, 1996
EXHIBIT 25
POWER OF ATTORNEY
The person whose signature appears below hereby authorizes Rosendo Ferran
and Robert J. Mellage, and each of them, with full power of substitution and
full power to act without the others, his true and lawful attorney-in-fact and
agent in his name place, and stead, to execute in the name and on behalf of each
such person, individually and as a director of Halsey Drug Co., Inc., a New York
corporation (the "Company"), and to file, the Registration Statement of the
Company on Form S-1 (the "Registration Statement"), and any and all amendments
to the Registration Statement, including any and all post-effective amendments.
WITNESS my hands on the date set forth below:
SIGNATURE DATE
- --------------------------------------------- ----------------
/s/ WILLIAM G. SKELLY August 1, 1996
.............................................
William G. Skelly